Category: RNA Diagnostics

RNA DIAGNOSTICS ANNOUNCES $5M SERIES A FINANCING ROUND LED BY iGAN PARTNERS

TORONTO – NOV 8, 2018 — Rna Diagnostics Inc., a Canadian company with a patented platform technology providing real-time cancer therapy guidance, announced today the closing of a $5 million Series A financing. The funding was led by iGAN Partners and includes new and  existing investors. MORE>>

RNA DIAGNOSTICS AIMS FOR 2010 CLINICAL LAUNCH OF BREAST CANCER TREATMENT GUIDANCE TEST

NEW YORK (GenomeWeb) – May 17, 2018 – Rna Diagnostics, a Canadian molecular diagnostics company, recently commenced a clinical trial to validate an assay it plans to commercialize that can be used to guide breast cancer treatment. The trial, called Breast Cancer Response Evaluation for Individualized Therapy (BREVITY), involves investigators from five countries and aims to enroll …

Continue reading

FIRST PATIENT ENROLLED IN BREVITY, RNA DIAGNOSTICS’ INTERNATIONAL VALIDATION TRIAL OF RDA™ IN PRIMARY BREAST CANCER

April 27, 2018 — Rna Diagnostics Inc., a Canadian company with a patented platform technology providing real-time cancer therapy guidance, announced enrollment of the first patient in the BREVITY trial at the Azienda Socio-Sanitaria Territoriale di Cremona in Cremona, Italy today. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) is an international prospective clinical trial to …

Continue reading

RNA DIAGNOSTICS INC. APPOINTS DR. MATTHEW P. GOETZ TO CLINICAL ADVISORY BOARD

TORONTO – JUL 6, 2017 — Rna Diagnostics Inc. announced today that Dr. Matthew P. Goetz, Consultant and Professor at Mayo Clinic, Rochester, MN has been appointed to the company’s Clinical Advisory Board (CAB). “Dr. Goetz brings a wealth of scientific knowledge and clinical trial experience in breast cancer to Rna Diagnostics,” said Jeremy Bridge-Cook, President …

Continue reading

RNA DIAGNOSTICS LAUNCHES BREVITY – INTERNATIONAL VALIDATION TRIAL TRIAL OF RDA™ IN BREAST CANCER

TORONTO, June 14, 2017 — Rna Diagnostics announced the launch of an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) as a tool for treatment management of primary breast cancer. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will include 500+ patients with invasive breast cancer, scheduled to receive neoadjuvant chemotherapy, in 40 centers across North …

Continue reading